These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15746584)

  • 1. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
    Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
    Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
    Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
    J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
    Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
    Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
    McArthur G
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
    Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
    Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
    Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
    Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
    Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
    Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
    Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
    PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
    Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
    Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
    J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
    Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
    World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.